title: Endometrial stromal sarcoma development after hysterectomy and tamoxifen therapy.
abstract: Tamoxifen therapy is well known for its success in adjuvant therapy for breast carcinoma; however, despite its benefits, the agents' estrogenic influence on the uterus, and subsequent endometrial cell proliferation may result in development of invasive uterine tumors. It has been estimated that tamoxifen may increase the risk of endometrial-based cancer two- to threefold, but uterine sarcomas remain relatively rare, accounting for 2 to 5 per cent of all uterine malignancies. We report the case of a 72-year-old woman having received tamoxifen for a breast carcinoma and having a hysterectomy nearly 30 years prior who presented with an intra-abdominal, omentum-based mass that on excision was identified as an endometrial stromal sarcoma.
authors.affiliation: Department of Surgery, Mercer University School of Medicine, Medical Center of Central Georgia, Macon, Georgia 31201, USA. benjie_christie@yahoo.com
authors.forename: D Benjamin
authors.initials: DB
authors.lastname: Christie
authors.forename: J Daniel
authors.initials: JD
authors.lastname: Day
authors.forename: Amy B
authors.initials: AB
authors.lastname: Moore
authors.forename: Jason R
authors.initials: JR
authors.lastname: Chapman
authors.forename: Don K
authors.initials: DK
authors.lastname: Nakayama
authors.forename: Arnold M
authors.initials: AM
authors.lastname: Conforti
mesh_terms: D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007044:Hysterectomy; D018203:Sarcoma, Endometrial Stromal / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000473:pathology / Q000601:surgery; D013629:Tamoxifen / Q000009:adverse effects*; D014057:Tomography, X-Ray Computed; D014594:Uterine Neoplasms / Q000628:therapy
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen